{"id":69620,"date":"2026-07-08T15:00:01","date_gmt":"2026-07-08T07:00:01","guid":{"rendered":"https:\/\/flcube.com\/?p=69620"},"modified":"2026-07-08T15:00:01","modified_gmt":"2026-07-08T07:00:01","slug":"mabwell-bioscience-secures-nmpa-approval-for-9mw5211-antibody-in-type-1-diabetes-expanding-autoimmune-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69620","title":{"rendered":"Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Mabwell (Shanghai) Bioscience Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688062:SHA\">SHA: 688062<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/2493:HKG\">HKG: 2493<\/a>) announced that its clinical trial application for <strong>9MW5211<\/strong> has received approval from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for the treatment of <strong>type 1 diabetes mellitus (T1DM)<\/strong>. The <strong>highly specific clearing antibody<\/strong> represents a novel immunomodulatory approach targeting the underlying autoimmune pathology of T1DM, with previous clinical approvals for <strong>inflammatory bowel disease<\/strong> and <strong>multiple sclerosis<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-amp-product-profile\" class=\"wp-block-heading\">Regulatory Milestone &amp; Product Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Mabwell (Shanghai) Bioscience Co., Ltd.<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>9MW5211<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Highly specific clearing innovative antibody<\/td><\/tr><tr><td><strong>Primary Indication<\/strong><\/td><td>Type 1 diabetes mellitus (T1DM)<\/td><\/tr><tr><td><strong>Additional Indications<\/strong><\/td><td>Inflammatory bowel disease, Multiple sclerosis<\/td><\/tr><tr><td><strong>Regulatory Body<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial approval<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>7 July 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-disease-context-amp-therapeutic-innovation\" class=\"wp-block-heading\">Disease Context &amp; Therapeutic Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>T1DM Pathophysiology<\/strong>: A <strong>chronic autoimmune condition<\/strong> characterized by immune-mediated destruction of <strong>insulin-producing beta cells<\/strong> in the pancreas, resulting in absolute insulin deficiency and persistent hyperglycemia requiring lifelong exogenous insulin therapy.<\/li>\n\n\n\n<li><strong>Mechanism of Action<\/strong>: 9MW5211 is designed to <strong>precisely intervene in key pathological mechanisms<\/strong> mediated by abnormal immune cells in autoimmune diseases, potentially halting or reversing the autoimmune attack on pancreatic beta cells\u2014representing a <strong>disease-modifying approach<\/strong> rather than symptomatic management.<\/li>\n\n\n\n<li><strong>Treatment Paradigm Shift<\/strong>: Current T1DM management remains centered on <strong>insulin replacement therapy<\/strong>, but emerging therapeutic goals emphasize achieving near-physiological glycemic control while avoiding hypoglycemia and diabetic ketoacidosis (DKA), improving quality of life, and reducing long-term complications.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Type 1 diabetes affects approximately <strong>4-5 million patients globally<\/strong>, with an estimated <strong>500,000-700,000 cases in China<\/strong>, predominantly diagnosed in children and young adults, creating significant unmet need for disease-modifying therapies.<\/p>\n\n\n\n<h2 id=\"h-platform-strategy-amp-pipeline-diversification\" class=\"wp-block-heading\">Platform Strategy &amp; Pipeline Diversification<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Multi-Indication Potential<\/strong>: The approval for T1DM marks the <strong>third autoimmune indication<\/strong> for 9MW5211, demonstrating the molecule&#8217;s broad applicability across immune-mediated disorders and validating Mabwell&#8217;s platform approach to autoimmune disease therapeutics.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Immunomodulatory Platform<\/strong>: 9MW5211 leverages Mabwell&#8217;s proprietary antibody engineering capabilities to achieve <strong>high specificity for pathogenic immune cell subsets<\/strong> while sparing normal immune function, potentially offering improved safety profiles compared to broad immunosuppressants.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Clinical Development Efficiency<\/strong>: The molecule&#8217;s progression across multiple indications enables <strong>shared preclinical data packages<\/strong> and potential <strong>accelerated regulatory pathways<\/strong> based on established safety profiles from other autoimmune trials.<\/p>\n\n\n\n<h2 id=\"h-market-implications-amp-competitive-landscape\" class=\"wp-block-heading\">Market Implications &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Opportunity<\/strong>: As one of the few <strong>disease-modifying approaches<\/strong> in clinical development for T1DM in China, 9MW5211 could capture significant market share if proven effective in preserving beta-cell function.<\/li>\n\n\n\n<li><strong>Premium Pricing Potential<\/strong>: Successful demonstration of disease modification would support premium pricing consistent with other biologic therapies for chronic autoimmune conditions.<\/li>\n\n\n\n<li><strong>Global Expansion Pathway<\/strong>: Positive results in China could support international clinical development, particularly given the universal nature of T1DM pathophysiology across populations.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking information regarding clinical development, regulatory approvals, and therapeutic innovation. Actual results may differ due to clinical trial outcomes, safety findings, regulatory decisions, and competitive developments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026070701876_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026070701876_c.\"><\/object><a id=\"wp-block-file--media-1588b4d6-d9d2-4a08-a5f7-e7a32e973e07\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026070701876_c.pdf\">2026070701876_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026070701876_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-1588b4d6-d9d2-4a08-a5f7-e7a32e973e07\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062, HKG: 2493) announced that its clinical trial application&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,39,4705,118,1129],"class_list":["post-69620","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-diabetes","tag-hkg-2493","tag-mabwell-bioscience","tag-sha-688062"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062, HKG: 2493) announced that its clinical trial application for 9MW5211 has received approval from China&#039;s National Medical Products Administration (NMPA) for the treatment of type 1 diabetes mellitus (T1DM). The highly specific clearing antibody represents a novel immunomodulatory approach targeting the underlying autoimmune pathology of T1DM, with previous clinical approvals for inflammatory bowel disease and multiple sclerosis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69620\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline\" \/>\n<meta property=\"og:description\" content=\"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062, HKG: 2493) announced that its clinical trial application for 9MW5211 has received approval from China&#039;s National Medical Products Administration (NMPA) for the treatment of type 1 diabetes mellitus (T1DM). The highly specific clearing antibody represents a novel immunomodulatory approach targeting the underlying autoimmune pathology of T1DM, with previous clinical approvals for inflammatory bowel disease and multiple sclerosis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69620\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-08T07:00:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69620#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69620\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline\",\"datePublished\":\"2026-07-08T07:00:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69620\"},\"wordCount\":485,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Diabetes\",\"HKG: 2493\",\"Mabwell Bioscience\",\"SHA: 688062\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69620#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69620\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69620\",\"name\":\"Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-08T07:00:01+00:00\",\"description\":\"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062, HKG: 2493) announced that its clinical trial application for 9MW5211 has received approval from China's National Medical Products Administration (NMPA) for the treatment of type 1 diabetes mellitus (T1DM). The highly specific clearing antibody represents a novel immunomodulatory approach targeting the underlying autoimmune pathology of T1DM, with previous clinical approvals for inflammatory bowel disease and multiple sclerosis.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69620#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69620\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69620#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062, HKG: 2493) announced that its clinical trial application for 9MW5211 has received approval from China's National Medical Products Administration (NMPA) for the treatment of type 1 diabetes mellitus (T1DM). The highly specific clearing antibody represents a novel immunomodulatory approach targeting the underlying autoimmune pathology of T1DM, with previous clinical approvals for inflammatory bowel disease and multiple sclerosis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69620","og_locale":"en_US","og_type":"article","og_title":"Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline","og_description":"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062, HKG: 2493) announced that its clinical trial application for 9MW5211 has received approval from China's National Medical Products Administration (NMPA) for the treatment of type 1 diabetes mellitus (T1DM). The highly specific clearing antibody represents a novel immunomodulatory approach targeting the underlying autoimmune pathology of T1DM, with previous clinical approvals for inflammatory bowel disease and multiple sclerosis.","og_url":"https:\/\/flcube.com\/?p=69620","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-08T07:00:01+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69620#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69620"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline","datePublished":"2026-07-08T07:00:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69620"},"wordCount":485,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Diabetes","HKG: 2493","Mabwell Bioscience","SHA: 688062"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69620#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69620","url":"https:\/\/flcube.com\/?p=69620","name":"Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-08T07:00:01+00:00","description":"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062, HKG: 2493) announced that its clinical trial application for 9MW5211 has received approval from China's National Medical Products Administration (NMPA) for the treatment of type 1 diabetes mellitus (T1DM). The highly specific clearing antibody represents a novel immunomodulatory approach targeting the underlying autoimmune pathology of T1DM, with previous clinical approvals for inflammatory bowel disease and multiple sclerosis.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69620#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69620"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69620#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69620","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69620"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69620\/revisions"}],"predecessor-version":[{"id":69624,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69620\/revisions\/69624"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69620"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69620"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69620"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}